Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

Ruben D. Restrepo, Andrew Tate, Joshua Coquat

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Introduction: Current clinical guidelines recommend long-acting bronchodilators as the mainstay of the pharmacotherapy of patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), in conjunction with long-acting beta-agonists (LABA), are routinely considered at severe and very severe stages of COPD when patients lack adequate response to single-therapy with LABAs. Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. Areas covered: This article attempts to review the most current evidence for using SAL/FLU in the management of COPD and summarizes the results of outcome measures reported in randomized controlled trials. Expert opinion: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.

    Original languageEnglish (US)
    Pages (from-to)1993-2002
    Number of pages10
    JournalExpert Opinion on Pharmacotherapy
    Volume14
    Issue number14
    DOIs
    StatePublished - Oct 2013

    Fingerprint

    Chronic Obstructive Pulmonary Disease
    Adrenal Cortex Hormones
    Therapeutics
    Bronchodilator Agents
    Expert Testimony
    Drug Combinations
    Salmeterol Xinafoate Drug Combination Fluticasone Propionate
    Randomized Controlled Trials
    Outcome Assessment (Health Care)
    Guidelines
    Drug Therapy
    Survival

    Keywords

    • Chronic obstructive pulmonary disease
    • Combination therapy
    • Exacerbations
    • Fluticasone propionate; inhaled corticosteroids long-acting bronchodilators
    • Salmeterol xinafoate

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Pharmacology

    Cite this

    Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease. / Restrepo, Ruben D.; Tate, Andrew; Coquat, Joshua.

    In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 14, 10.2013, p. 1993-2002.

    Research output: Contribution to journalArticle

    @article{2771a166a464484a8e086d0b0cc9c1ff,
    title = "Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease",
    abstract = "Introduction: Current clinical guidelines recommend long-acting bronchodilators as the mainstay of the pharmacotherapy of patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), in conjunction with long-acting beta-agonists (LABA), are routinely considered at severe and very severe stages of COPD when patients lack adequate response to single-therapy with LABAs. Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. Areas covered: This article attempts to review the most current evidence for using SAL/FLU in the management of COPD and summarizes the results of outcome measures reported in randomized controlled trials. Expert opinion: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.",
    keywords = "Chronic obstructive pulmonary disease, Combination therapy, Exacerbations, Fluticasone propionate; inhaled corticosteroids long-acting bronchodilators, Salmeterol xinafoate",
    author = "Restrepo, {Ruben D.} and Andrew Tate and Joshua Coquat",
    year = "2013",
    month = "10",
    doi = "10.1517/14656566.2013.823949",
    language = "English (US)",
    volume = "14",
    pages = "1993--2002",
    journal = "Expert Opinion on Pharmacotherapy",
    issn = "1465-6566",
    publisher = "Informa Healthcare",
    number = "14",

    }

    TY - JOUR

    T1 - Evaluation of salmeterol xinafoate plus fluticasone propionate for the treatment of chronic obstructive pulmonary disease

    AU - Restrepo, Ruben D.

    AU - Tate, Andrew

    AU - Coquat, Joshua

    PY - 2013/10

    Y1 - 2013/10

    N2 - Introduction: Current clinical guidelines recommend long-acting bronchodilators as the mainstay of the pharmacotherapy of patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), in conjunction with long-acting beta-agonists (LABA), are routinely considered at severe and very severe stages of COPD when patients lack adequate response to single-therapy with LABAs. Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. Areas covered: This article attempts to review the most current evidence for using SAL/FLU in the management of COPD and summarizes the results of outcome measures reported in randomized controlled trials. Expert opinion: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.

    AB - Introduction: Current clinical guidelines recommend long-acting bronchodilators as the mainstay of the pharmacotherapy of patients with chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS), in conjunction with long-acting beta-agonists (LABA), are routinely considered at severe and very severe stages of COPD when patients lack adequate response to single-therapy with LABAs. Although the study methodologies evaluating the clinical effectiveness of the combination therapy using salmeterol and fluticasone (SAL/FLU) for patients with COPD have been questioned, a number of studies have suggested that using ICS, in combination with a LABA agent, may improve survival of patients with COPD. Areas covered: This article attempts to review the most current evidence for using SAL/FLU in the management of COPD and summarizes the results of outcome measures reported in randomized controlled trials. Expert opinion: Until new forms of drug combinations are made available, the use of dual-therapy containing a LABA and ICS remain as the most logical and appropriate approach for the treatment of patients suffering from severe and very severe COPD with repeated exacerbations.

    KW - Chronic obstructive pulmonary disease

    KW - Combination therapy

    KW - Exacerbations

    KW - Fluticasone propionate; inhaled corticosteroids long-acting bronchodilators

    KW - Salmeterol xinafoate

    UR - http://www.scopus.com/inward/record.url?scp=84884236530&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84884236530&partnerID=8YFLogxK

    U2 - 10.1517/14656566.2013.823949

    DO - 10.1517/14656566.2013.823949

    M3 - Article

    VL - 14

    SP - 1993

    EP - 2002

    JO - Expert Opinion on Pharmacotherapy

    JF - Expert Opinion on Pharmacotherapy

    SN - 1465-6566

    IS - 14

    ER -